LifeStance Health Group (LFST) stock has been on an upward trajectory, gaining 11.6% over the past four weeks. Wall Street analysts see even more potential, with an average price target of $7.93, suggesting a 26.7% upside. However, relying solely on analysts’ price targets can be risky. While analysts may have insights into company fundamentals, their price targets can be influenced by business incentives, and their accuracy is often questioned. Despite this, the strong agreement among analysts regarding LFST’s earnings prospects, with upward revisions to EPS estimates, provides a more compelling reason for optimism. This trend in earnings estimate revisions has historically been a reliable predictor of stock price gains. LFST’s current Zacks Rank #2 (Buy) further strengthens its potential for upside in the near term.